Sartorius Bioprocess Solutions & SUT Demand Outlook – Customer Assessment – Part 2

  • Public Equity
  • Healthcare
  • Europe


Executive at a global CDMO


  • Key customer purchasing criteria for bioprocessing equipment across upstream and downstream bioprocessing workflows
  • Incumbent benchmarking vs key purchasing criteria – Sartorius (ETR: SRT) vs Danaher (NYSE: DHR), Thermo Fisher (NYSE: TMO), Repligen (NASDAQ: RGEN) and Merck Millipore (ETR: MRK)
  • Evolving SUT (single-use technology) requirements and vendor positioning across modalities and end markets including mAbs (monoclonal antibodies), C&GT (cell and gene therapy) and ATMP (advanced therapeutic medicinal products)
  • Mid-to-long-term price and volume outlook for SUT bioprocessing equipment, touching on dynamics with CDMOs (contract development and manufacturing organisations)


Gain access to Premium Content

Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.

    One week, unlimited access to over 40,000 transcripts
The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited